Acceleron Pharma Inc Shares Close in on 52-Week High - Market Mover

The shares closed 1.7% below its 52-week high of $146.15, with trading volume lower than its 30 day average

Mar 22, 2021 by Kwhen Finance Editors

Acceleron Pharma Inc Shares Close in on 52-Week High - Market Mover
Acceleron Pharma Inc shares closed today at 1.7% below its 52 week high of $146.15, giving the company a market cap of $8B. The stock is currently up 12.3% year-to-date, up 99.5% over the past 12 months, and up 420.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.7%, and the S&P 500 fell 0.8%.

Trading Activity

  • Trading volume this week was 79.0% higher than the 20-day average.
  • Beta, a measure of the stock’s volatility relative to the overall market stands at 0.7.

Technical Indicators

  • The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
  • MACD, a trend-following momentum indicator, indicates an upward trend.
  • The stock closed below its Bollinger band, indicating it may be oversold.

Fundamentals & Catalysts

  • Over the past 12 months the company generated $-163,461,000 in earnings before interest and taxes from $92 million in revenue. It currently holds $849 million in cash and $60 million in debt.
  • Its forward price-to-earnings (P/E) ratio of 0 is higher than its current P/E ratio of -52.38, implying that analysts are expecting a decrease in earnings.
  • The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at 2.18. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
  • The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 1.09 which means it currently has $1.09 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
  • The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 9.64. This means that the stock is trading at a premium of 10 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
  • The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 89.11.
  • The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 79.92.

P/E

-52.38

EBITDA

$-163,461,000

P/Book

9.64

Mkt Cap

$8B

P/Sales

89.11

Revenue

$92M

EPS (TTM)

-2.92

PEG Ratio

2.18

EV/Revenue

79.92

Total Cash

$849M

Debt/Equity

1.09

Forward P/E

0.00

Current Debt

$60M

Gross Profit

$92M

Dividend Date

-

Earnings Date

2021-02-25

Profit Margin

-1.79

Revenue/Share

1.53

Total Revenue

$92M

Enterprise Val

$7B

Put/Call Ratio

1.02

Revenue/Employee

411213.33

Market Comparative Performance

  • The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis
  • The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis
  • The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis
NameDoD %ΔYTD %Δ1 Yr %52-Week H %52-Week L %
Acceleron Pharma Inc4.112.399.5
Dow Jones Industrial Average0.47.573.9-2.069.2
S&P 500 Index0.84.573.0-1.781.6
Health Care0.92.452.7-4.053.1

Peer Group Comparative Performance

  • The company's stock price performance year-to-date lags the peer average by -29.3%
  • The company's stock price performance over the past 12 months beats the peer average by 42.6%
NameMKT CAP (USD)P/EYTD %Δ1 Yr %Δ52-Week H %52-Week L %
Acceleron Pharma IncXLRN-52.412.399.5
Peer AvgN/A9.217.469.8-3.610.1
Johnson & JohnsonJNJ28.72.637.5-8.342.8
Pfizer Inc.PFE20.9-1.129.2-16.927.6
Amgen Inc.AMGN19.67.834.3
Regeneron Pharmaceuticals Inc.REGN14.50.010.2
bluebird bio Inc.BLUE-3.4-28.2-36.1
Sangamo Therapeutics Inc.SGMO-15.9-12.9126.1
Onconova Therapeutics Inc.ONTX0153.3287.0

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?

Tags: